4-(quinazolin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester | 853680-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(quinazolin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-quinazolin-4-yloxypiperidine-1-carboxylate
• CAS: 853680-41-8
• 化学式: C₁₈H₂₃N₃O₃
• 分子量: 329.399
• InChiKey: VMTVVQWTZQPRPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氯喹唑啉 、 N-Boc-4-羟基哌啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以76%的产率得到4-(quinazolin-4-yloxy)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] AKT PROTEIN KINASE INHIBITORS
  [FR] INHIBITEURS DE LA PROTEINE KINASE AKT

  摘要：

  公开号：

  WO2005051304A3

文献信息

• AKT protein kinase inhibitors
  申请人：Mitchell S. Ian

  公开号：US20050130954A1

  公开（公告）日：2005-06-16

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供化合物，包括已解决的对映体、二对映异构体、溶剂化物和药学上可接受的盐，其包括公式：A-L-CR，其中CR是一个环核心基团，L是一个连接基团，A如此处所定义。同时提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗增殖性疾病如癌症的方法。
• AKT PROTEIN KINASE INHIBITORS
  申请人：Mitchell Ian S.

  公开号：US20100168123A1

  公开（公告）日：2010-07-01

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了化合物，包括已分离的对映体、非对映异构体、溶剂化物和药学上可接受的盐，其包括式子：A-L-CR，其中CR是一个环状核心基团，L是一个连接基团，A如上所定义。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗增殖性疾病，如癌症的方法。
• QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY
  申请人：Shenzhen Chipscreen Biosciences Co., Ltd.

  公开号：EP3858813A1

  公开（公告）日：2021-08-04

  Provided is a quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity, specifically, provided is a compound of general Formula (I) or pharmaceutically acceptable salt thereof, its pharmaceutical composition, preparation method and use in the manufacture of a medicament for immunomodulating and preventing and/or treating of a disease associated with IDO expression abnormality and/or tryptophan metabolism abnormality. Also provided is use of a combination medication of the quinoline derivative and HDAC inhibitor and its use in the manufacture of an anti-tumor drug.         A-X-B-Y-M     Formula (I)

  本发明提供了一种具有吲哚胺-2,3-二氧化酶抑制活性的喹啉衍生物，具体地说，提供了通式（I）的化合物或其药学上可接受的盐、其药物组合物、制备方法以及在制造用于免疫调节和预防和/或治疗与IDO表达异常和/或色氨酸代谢异常相关的疾病的药物中的用途。此外，还提供了喹啉衍生物和 HDAC 抑制剂的联合用药及其在制造抗肿瘤药物中的用途。 A-X-B-Y-M 分子式 (I)
• QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY
  申请人：SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.

  公开号：US20210379052A1

  公开（公告）日：2021-12-09

  Provided is a quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity, specifically, provided is a compound of general Formula (I) or pharmaceutically acceptable salt thereof, its pharmaceutical composition, preparation method and use in the manufacture of a medicament for immunomodulating and preventing and/or treating of a disease associated with IDO expression abnormality and/or tryptophan metabolism abnormality. Also provided is use of a combination medication of the quinoline derivative and HDAC inhibitor and its use in the manufacture of an anti-tumor drug. A-X—B—Y-M   Formula (I)
• US8680114B2
  申请人：——

  公开号：US8680114B2

  公开（公告）日：2014-03-25